HOME > REGULATORY
REGULATORY
- Japan Adopts New Evaluation Method for Nitrosamine Impurities Risks
August 7, 2023
- Japan’s Healthcare Spending Up 11.0% in FY2021: IPSS Report
August 7, 2023
- Despite Increase in Reviewers, Japan Faces Backlog of Over 4,000 Health Damage Claims for COVID Jabs
August 4, 2023
- With Generics Now in Common Use, It’s Time for Debate on LLP Copay: Payers
August 4, 2023
- Japan to Set Up New Forum on Dementia Measures: PM
August 4, 2023
- 30% of Eligible Population Unaware of HPV Vaccine: Survey
August 4, 2023
- Payers Want Phase-Out of Medical Fee Premiums for Generic Use; HCPs Eye Change in Entry Pricing
August 3, 2023
- Chuikyo OKs Plan to Move Back Medical Fee Revisions to June from FY2024; Drug Price Updates to Remain in April
August 3, 2023
- Industry Calls for Excluding Orphan Drugs from Cost-Effectiveness Assessment
August 3, 2023
- Chuikyo Reps Criticize Manufacturers’ Price Cuts after Unprofitability Re-Pricing
August 3, 2023
- Relief Claims OK’ed for 38 More Deaths after COVID Vaccination
August 2, 2023
- Generics Panel Initiates Debate toward Proposing Stable Supply Measures, Interim Report Slated for October
August 1, 2023
- Pharma Regulation Panel to Discuss Need for PI Japanese Data on Aug. 7
August 1, 2023
- Perjeta/Herceptin SC Combo, 1st Stelara, G-Lasta Biosimilars in Line for Japan Approval
August 1, 2023
- Japan Panel Shelves Decision on Shionogi’s COVID Vaccine over Efficacy Data
August 1, 2023
- First Two Homegrown COVID-19 Jabs Up for MHLW Panel Review on July 31
July 31, 2023
- Japan Safety Panels Recognize 2nd Death Possibly Linked to COVID Vaccine
July 31, 2023
- Japan to Buy 20 Million Doses of Pfizer COVID Jab, 5 Million from Moderna
July 28, 2023
- Japan Likely to Slash Moderna Vaccine Purchase, Pfizer Single-Sourcing Plan Nixed
July 28, 2023
- Chuikyo Medical Device Pricing Body Calls for Clearer Reimbursement Criteria for SaMDs
July 27, 2023
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…